|Bid||270.15 x 800|
|Ask||270.62 x 800|
|Day's range||265.88 - 271.86|
|52-week range||212.85 - 317.17|
|Beta (5Y monthly)||1.03|
|PE ratio (TTM)||9.62|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||29 Mar 1994|
|1y target est||N/A|
BURLINGTON, N.C., January 26, 2022--For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSE: LH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progr
GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.
BURLINGTON, N.C., January 10, 2022--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.